Butterfly Network Inc (BFLY) Investment Analysis

1. Executive Summary

Butterfly Network Inc. (NYSE: BFLY) stands at a pivotal juncture in its corporate evolution as of late 2025, representing a classic case study of a high-growth "disruptor" attempting to transition into a disciplined, operationally sustainable medical technology enterprise. Founded by Dr. Jonathan Rothberg with the ambitious, almost philanthropic vision of democratizing medical imaging through semiconductor technology, the company has spent the last few years navigating the treacherous path from a Speculative Purpose Acquisition Company (SPAC) debut to the harsh realities of the public markets. As of the third quarter of 2025, the company has begun to demonstrate tangible evidence of a successful strategic pivot under the leadership of CEO Joseph DeVivo, moving away from a "growth at all costs" mentality toward a pragmatic focus on enterprise software adoption, gross margin expansion, and cash flow preservation.

The core of Butterfly’s value proposition remains its proprietary Ultrasound-on-Chip™ technology. In an industry historically dominated by piezoelectric crystal-based transducers—complex, labor-intensive, and fragile components that have defined ultrasound physics for half a century—Butterfly introduces a paradigm shift by utilizing Capacitive Micromachined Ultrasonic Transducers (CMUT) fabricated on a single silicon wafer. This architectural difference is not merely a manufacturing detail; it is the fundamental economic engine of the company. It allows for a single probe to emulate linear, curved, and phased array transducers, performing whole-body imaging at a fraction of the cost of legacy cart-based systems. The company’s trajectory is no longer solely defined by the novelty of this hardware but by its integration into a broader digital ecosystem, specifically its new "Compass AI" suite designed to solve the administrative and billing inefficiencies that plague Point-of-Care Ultrasound (POCUS) adoption in large health systems.

Financially, the company has achieved significant milestones in 2025 that suggest a stabilizing business model. For the third quarter of 2025, Butterfly reported revenue of $21.5 million, representing a 5% year-over-year growth. While this top-line growth is modest compared to the hyper-growth expectations of its SPAC era, the quality of this revenue has improved, driven by higher Average Selling Prices (ASPs) from its third-generation probe, the iQ3, and a strategic shift toward high-margin software services. Most critically for the investment thesis, the company reduced its quarterly cash burn to a record low of $3.9 million in Q3 2025 , effectively extending its cash runway well into the future without the immediate need for dilutive financing—a major de-risking event for shareholders given the high cost of capital in the current macroeconomic environment.

However, the path forward is fraught with competitive and execution risks. The handheld ultrasound market is no longer a blue ocean; it is a fiercely contested battleground. Incumbents like GE HealthCare, with its Vscan Air, and Philips, with its Lumify, have leveraged deep hospital procurement relationships and perceived superior image quality to defend their market share. Furthermore, niche players like Clarius have captured the high-end specialist market. Butterfly’s counter-strategy relies heavily on regulatory arbitrage—specifically the potential expiration of RoHS exemptions for lead-based probes in Europe—and the "platformization" of its device through AI automation. The company remains unprofitable on a GAAP basis, posting a net loss of $34.0 million in Q3 2025, exacerbated by a substantial $17.4 million inventory write-down that raises questions about past demand forecasting accuracy.

This report provides an exhaustive, expert-level analysis of Butterfly Network. It dissects the interplay between the company’s semiconductor moat and the practical realities of hospital adoption cycles. It evaluates the potential financial windfall from its Compass AI software, analyzes the impending regulatory shifts in the European Union, and subjects the company’s valuation to rigorous scenario testing to determine if the current share price represents a deep-value entry point or a value trap in a crowded MedTech sector.

2. Business Drivers & Strategic Overview

To understand the investment potential of Butterfly Network, one must look beyond the device itself and analyze the converging forces of semiconductor economics, enterprise software dynamics, and clinical workflow evolution. The company’s strategy has shifted from a direct-to-consumer/individual clinician model toward a robust enterprise B2B approach, a transition that is reshaping its revenue quality and competitive posture.

The Semiconductor Moat: Physics as a Business Model

The foundational driver of Butterfly’s business, and its most durable competitive advantage, is its Ultrasound-on-Chip™ technology. Traditional ultrasound transducers operate on the piezoelectric effect, using crystals (ceramics containing lead, zirconium, and titanium) to generate sound waves. These crystals must be precision-cut, tuned to specific frequencies, and wired individually. This manufacturing complexity results in high unit costs and necessitates different probes for different anatomical depths—a linear probe for superficial veins, a curved probe for abdomens, and a phased array for cardiac imaging.

Butterfly’s technology utilizes thousands of programmable micro-machined sensors on a semiconductor chip. This confers several strategic economic advantages that differentiate it from legacy manufacturers:

• Unified Manufacturing Process: By leveraging standard CMOS semiconductor manufacturing processes (similar to those used for computer processors), Butterfly benefits from the scalability of the silicon supply chain. As production volume increases, the unit cost per chip decreases, adhering to the economics of Moore’s Law rather than the linear cost scaling of piezoelectric manufacturing. This allows Butterfly to maintain gross margins (adjusted) in the mid-60% range even at a lower price point than competitors.

• Frequency Agility: A single silicon chip can be dynamically tuned to emit a wide range of frequencies. This versatility allows the Butterfly iQ3 to function as a "whole-body" imager, eliminating the need for hospitals to purchase and maintain multiple specialized probes. For a hospital procurement department, this consolidation represents a significant reduction in capital expenditure and maintenance complexity.

• Thermal Management and Power Efficiency: The integration of the transducer elements with signal processing electronics on the same chip reduces power consumption and heat generation. While early generations (iQ+) struggled with thermal limits during prolonged scanning, the new P4.3 and upcoming P5.1 architectures have largely mitigated this, allowing for continuous monitoring capabilities that are critical for complex procedures.

The Pivot to Enterprise Software: Compass AI

In 2025, the most significant strategic driver for Butterfly is not hardware, but the commercialization of its Compass AI enterprise software. The handheld ultrasound market has historically been plagued by a "billing leakage" problem. Hospitals purchase fleet devices, but clinicians—often overwhelmed by administrative burdens—fail to document scans or submit them for reimbursement. This renders the devices a cost center rather than a revenue generator.

Compass AI is designed to reverse this dynamic by automating the workflow.

• Revenue Capture: The software integrates ambient voice dictation and AI-powered quality assurance (QA) agents to automate documentation. Management claims that traditional workflows capture only about 15% of compliant studies, leaving 85% unbilled. Compass AI aims to enable documentation compliance rates of up to 94%, potentially generating up to five times more revenue for health systems from the same clinical volume.

• The "Easy Money" Pitch: CEO Joseph DeVivo has explicitly positioned this as a path to "easy money" for hospitals—capturing value that was already being generated but lost to administrative friction. This shifts the sales conversation from clinical utility (which is subjective) to financial ROI (which is objective), a crucial pivot in a tight hospital capital environment.

• SaaS Economics: Increasing the attach rate of Compass AI to iQ3 hardware sales shifts Butterfly’s revenue mix toward high-margin, recurring software revenue. This reduces the volatility associated with hardware capital cycles and improves long-term customer retention (stickiness) through deep integration with Electronic Health Records (EHR) and Picture Archiving and Communication Systems (PACS).

Hardware Innovation: The iQ3 and Future Roadmap

The launch of the Butterfly iQ3 in early 2024 was a corrective measure to address the limitations of the iQ+. The device features a smaller probe face (17% smaller) for better intercostal access (imaging between ribs), faster charging (2x speed), and improved image resolution.

• Average Selling Price (ASP) Uplift: The iQ3 commands a higher price point than its predecessors. In Q3 2025, international revenue grew 4% driven largely by the higher ASP of the iQ3, which accounted for approximately 85% of total probe volume. This successful up-tiering of the customer base is the primary driver of the company's gross margin expansion to an adjusted 63.9%.

• The P5.1 and Apollo Chips: Looking further ahead, the company has confirmed the development of the P5.1 chip, which is moving to fabrication, and the Apollo AI chip. These next-generation semiconductors are expected to further miniaturize the technology, potentially enabling wearable form factors or "patch-based" continuous ultrasound monitoring. This would expand the Total Addressable Market (TAM) from episodic diagnostic scans to continuous patient monitoring, a market segment with significantly higher recurring revenue potential.

The Regulatory Wedge: RoHS Compliance in Europe

A distinct, under-pricing strategic driver is the European Union’s Restriction of Hazardous Substances (RoHS) directive. Traditional piezoelectric ultrasound probes rely on lead-based crystals (PZT). Currently, the medical device industry operates under a temporary exemption (Annex IV, Exemption 14) allowing the use of lead because "no viable alternative" existed.

Butterfly argues that its Ultrasound-on-Chip technology is the viable lead-free alternative.

• Lobbying for Exclusion: Butterfly is actively lobbying the European Commission to let the exemption for handhelds expire, arguing that continued use of lead is unnecessary given their compliant technology.

• Competitive Implication: If the EU agrees and revokes the exemption, competitors like GE and Philips could theoretically be banned from selling their current lead-based handheld probes in the EU market until they develop lead-free alternatives. This would grant Butterfly a temporary regulatory monopoly or forced market share capability in the region. This "regulatory arbitrage" represents a significant asymmetric upside call option for the business that is largely uncorrelated with broader market trends.

Ecosystem Expansion: "Butterfly Garden"

Recognizing that no single company can build every diagnostic AI algorithm, Butterfly launched Butterfly Garden, an AI marketplace.

• Third-Party Integration: Partnerships with companies like Deski (HeartFocus) allow Butterfly to offer FDA-cleared, specialized AI tools (e.g., automated echocardiography) without bearing the full R&D burden.

• Flywheel Effect: As more third-party apps populate the ecosystem, the Butterfly hardware becomes more valuable to specialists (cardiologists, OB/GYN, urologists), creating a network effect similar to the Apple App Store. This openness contrasts with the "walled garden" approach of some legacy MedTech competitors.

Competitive Landscape Analysis

The handheld ultrasound market is a triopoly of premium providers, each with distinct strengths:

1. GE HealthCare (Vscan Air): The primary formidable competitor. The Vscan Air offers wireless dual-probe technology (a physical linear probe on one side, curved on the other). User reviews frequently cite the Vscan Air as having superior image quality, particularly for cardiac applications, due to the mature processing of piezoelectric crystals. GE leverages massive existing hospital install bases to bundle Vscan units with large MRI/CT deals, a distribution advantage Butterfly lacks.

2. Philips (Lumify): Known for excellent image quality but historically required a cabled connection to a tablet/phone. Philips offers a subscription-based model (SaaS-like hardware rental) which lowers upfront capital costs. However, the requirement for separate probes (linear vs. phased array) reduces the "all-in-one" convenience compared to the iQ3.

3. Clarius: Positions itself as the high-definition choice for specialists (plastic surgeons, MSK, anesthesia). Clarius probes are wireless and offer arguably the highest resolution in the handheld class but are larger, heavier, and more expensive. They are preferred by users who prioritize absolute image fidelity over the "one-probe-fits-all" convenience.

Butterfly’s strategic positioning in this landscape is defined by the balance of versatility and software intelligence. While it may not win a pure pixel-peeping contest against a high-end Clarius probe for a specific nerve block, its ability to scan a heart, a lung, and a bladder with one device—coupled with the Compass AI workflow for billing—makes it the superior "fleet" choice for hospital administrators focused on system-wide efficiency.

3. Financial Performance & Valuation

Butterfly Network's financial narrative in 2024-2025 has been defined by a rigorous focus on operational efficiency and a pivot toward sustainable unit economics. The "growth at all costs" era of the SPAC boom has been replaced by a disciplined march toward breakeven.

3.1 Historical Performance (2024-2025)

Revenue Dynamics: For the third quarter of 2025, Butterfly reported total revenue of $21.5 million, a 5% increase year-over-year from $20.6 million in Q3 2024.

• Domestic vs. International: U.S. revenue stood at $16.1 million, while international revenue grew 4% to $5.4 million. The international growth was primarily driven by the launch of the iQ3 in European markets, where the higher price point (ASP uplift) compensated for volume fluctuations.

• Seasonality: The dip in revenue from Q2 2025 ($23.4 million) to Q3 2025 ($21.5 million) highlights the seasonal nature of the medical capital equipment market, where the third quarter is typically the softest period before the Q4 budget flush.

• Guidance: Management reaffirmed full-year 2025 revenue guidance of $91 million to $95 million, implying a projected year-over-year growth of approximately 13%. This guidance suggests a strong Q4 ramp, driven by enterprise software deals closing before year-end.

Margin Analysis: The divergence between GAAP and Adjusted gross margins in Q3 2025 paints a picture of a company cleaning up its balance sheet.

• Adjusted Gross Margin: Expanded to 63.9% in Q3 2025, up significantly from 60.0% in the prior year period. This expansion is a direct result of the mix shift toward the higher-margin iQ3 probe and operational efficiencies in manufacturing. It validates the long-term thesis that semiconductor-based ultrasound can yield software-like hardware margins.

• GAAP Gross Margin: Collapsed to (17.5)% due to a massive $17.4 million non-cash inventory write-down. This write-down was related to excess and obsolete inventory of previous-generation products (iQ+) and components. While optically alarming, this "kitchen sinking" event is likely a strategic move to clear legacy assets from the books, allowing future quarters to reflect the cleaner economics of the iQ3 and software lines.

Operating Expenses and Cash Flow:

• Cash Burn: The most bullish metric in the Q3 report was the reduction in quarterly cash burn to $3.9 million, a record low for the company. This compares to burns of $10M+ in previous years.

• Expense Control: Total operating expenses (excluding stock-based compensation) were $23.7 million, essentially flat year-over-year. This demonstrates that the company is growing its top line without inflating its fixed cost base—a hallmark of operating leverage.

• Net Loss: The GAAP net loss was $34.0 million, primarily driven by the inventory write-down. Adjusted EBITDA loss, which excludes the write-down and SBC, narrowed to $8.1 million.

Balance Sheet Strength: As of September 30, 2025, Butterfly held $144.2 million in cash and cash equivalents. With a burn rate now stabilized below $5 million per quarter, the company has a theoretical cash runway extending well beyond 5 years. This removes the existential risk of insolvency that plagues many small-cap MedTech firms and eliminates the near-term need for dilutive equity raises.

3.2 Valuation Analysis

As of early December 2025, Butterfly Network shares trade at approximately $3.06, giving the company a market capitalization of roughly $773 million.

Key Valuation Metrics:

• Enterprise Value (EV): ~$629 million (Market Cap $773M - Net Cash ~$144M).

• EV/Revenue (TTM): Based on TTM revenue of ~$88.5 million, the stock trades at ~7.1x EV/Revenue.

• EV/Revenue (2025E): Based on the midpoint of guidance ($93 million), the forward multiple is ~6.8x.

Peer Comparison: To contextualize this valuation, we must compare BFLY to a basket of peers ranging from high-growth digital health to mature imaging conglomerates.

Valuation Synthesis: Butterfly trades at a significant premium to mature players like GE HealthCare (2.2x) and even its direct portable MRI peer Hyperfine (5.0x). This premium suggests that the market is pricing in substantial credit for the "SaaS transition"—valuing Butterfly closer to a high-growth software company than a hardware device maker. Investors are essentially paying for the potential of the Compass AI platform to drive margin expansion and recurring revenue. If revenue growth remains stuck in the low-teens (~13%), this 7.1x multiple is at risk of compression toward the hardware mean of 3x-4x. However, if growth re-accelerates to 20%+ driven by software, the multiple is defensible.

4. Risk Assessment & Macroeconomic Considerations

While the turnaround story is compelling, Butterfly Network faces a confluence of macroeconomic, operational, and competitive risks that could derail its trajectory.

4.1 Macroeconomic & Hospital Spending Environment

• Capital Budget Constriction: The healthcare sector in 2025 continues to grapple with labor shortages and wage inflation, squeezing hospital operating margins. While POCUS devices are relatively low-cost ($3,000–$4,000) compared to CT scanners, they are often classified as discretionary capital equipment. Hospital CFOs, facing rising supply chain costs (projected to increase 2.41% in 2026 ), are prioritizing revenue-generating equipment (like MRI/CT) over diagnostic tools that have historically been viewed as cost centers. This "macro headwind" was explicitly cited by management as a cause for deal delays in Q2/Q3 2025.

• Interest Rates: Although rates may have stabilized, the cost of capital remains high relative to the ZIRP (Zero Interest Rate Policy) era. This impacts the leasing and financing models for hospital equipment, potentially lengthening sales cycles.

4.2 Adoption Barriers & "Shelfware" Risk

• The Proficiency Gap: The single biggest barrier to POCUS adoption is not price, but user proficiency. Ultrasound is highly operator-dependent. Unlike an ECG which provides an automated readout, an ultrasound requires manual dexterity to acquire the image and cognitive skill to interpret it. If Butterfly cannot sufficiently train nurses and hospitalists—or automate image acquisition via AI—the devices risk becoming "shelfware," gathering dust in a drawer. If utilization drops, the recurring revenue from software subscriptions (Compass AI) will churn.

• User Feedback on Image Quality: While the iQ3 is an improvement, user forums (Reddit, etc.) continue to feature debates regarding image quality. Some specialists argue that the iQ3 still lags behind the GE Vscan Air in cardiac clarity and the Clarius in MSK resolution. If the "jack-of-all-trades" chip cannot match the fidelity of specialized crystals, Butterfly may be locked out of high-end specialist markets.

4.3 Regulatory & Supply Chain Risks

• RoHS Uncertainty: The European lead exemption strategy is a double-edged sword. If the EU renews the exemption for lead-based probes (as lobbied by the COCIR trade association), Butterfly loses a massive potential catalyst. Furthermore, if the regulatory tide turns against all complex electronics due to other environmental concerns, Butterfly’s own supply chain could face scrutiny.

• Inventory Management: The $17.4 million write-down in Q3 2025 is a significant red flag. It indicates a failure in demand forecasting for the legacy iQ+ product. Continued inability to manage product transitions cleanly could lead to further capital destruction and weigh on GAAP profitability.

• Single-Source Manufacturing: As a fabless semiconductor company, Butterfly relies on partners like TSMC for chip fabrication. Any geopolitical escalation in the Taiwan Strait represents a catastrophic tail risk for the company’s ability to produce its core component.

4.4 Financial Risks

• Path to GAAP Profitability: While cash burn is impressively low, the company remains deeply unprofitable on a GAAP basis due to depreciation and stock-based compensation (SBC). SBC is a real cost to shareholders via dilution. With the share count likely to increase to attract and retain talent, the "per share" value creation faces a headwind even if the enterprise value grows.

5. 5-Year Scenario Analysis

This analysis projects Butterfly Network’s share price trajectory through 2030 based on three distinct scenarios. These scenarios are grounded in the execution of the Compass AI pivot, the success of the iQ3/iQ4 hardware cycles, and the regulatory landscape in Europe.

Core Assumptions Across All Scenarios:

• Dilution: Assumed annual share count dilution of ~3% due to Stock-Based Compensation (SBC), growing the share count from ~253 million to ~293 million by 2030.

• Net Cash: The company utilizes its $144M cash pile to reach self-funding status; no massive equity raises are modeled, but cash interest income provides a small buffer.

Scenario A: High Case – "The Standard of Care" (20% Probability)

Narrative: Butterfly successfully crosses the chasm from a "nice-to-have" gadget to the "standard of care" for bedside assessment. Compass AI proves its ROI thesis (5x revenue capture), compelling large health systems to deploy fleets of probes to every doctor and nurse. The EU revokes RoHS exemptions for lead-based probes in 2027, severely hampering competitors in Europe. The P5.1 chip enables a new "wearable" form factor in 2027, opening a continuous monitoring revenue stream.

• Revenue Growth: Re-accelerates to 25% CAGR (2025-2030) as software attach rates soar.

• 2030 Revenue: ~$285 million.

• Profitability: Software mix reaches 45% of revenue, driving gross margins to 70% and EBITDA margins to 20% (SaaS-like economics).

• Valuation: Market rewards the "Medical SaaS" profile with a 6.0x EV/Revenue multiple.

Scenario B: Base Case – "Steady Niche Growth" (50% Probability)

Narrative: Butterfly continues to grow but remains a tool primarily for ER doctors, intensivists, and progressive educators. Compass AI sees moderate adoption but faces friction in changing hospital billing workflows. Competitors (GE, Philips) successfully defend the cardiology and radiology segments. The company achieves cash flow breakeven in 2027, but top-line growth stabilizes in the low-teens.

• Revenue Growth: Maintains a 12% CAGR (2025-2030).

• 2030 Revenue: ~$165 million.

• Profitability: Software mix stabilizes at ~30-35%. EBITDA margins reach 10% as the company focuses on efficiency over hyper-growth.

• Valuation: The multiple compresses to a standard MedTech hardware rating of 3.5x EV/Revenue, reflecting the slower growth profile.

Scenario C: Low Case – "Commoditization" (30% Probability)

Narrative: Handheld ultrasound becomes a race to the bottom on price. Cheap competitors from Asia or aggressive discounting from GE erode ASPs. The software "billing" pitch fails to gain traction against incumbent PACS/EHR systems (Epic/Cerner building their own modules). The RoHS exemption is renewed indefinitely. Demand forecasting errors continue, leading to more write-downs.

• Revenue Growth: Stagnates at 3% CAGR (tracking medical inflation).

• 2030 Revenue: ~$108 million.

• Profitability: Software mix <25% (high churn). EBITDA margins remain negative (-5%) or barely breakeven.

• Valuation: The stock is priced as a distressed hardware manufacturer at 1.5x EV/Revenue.

Projected Share Price Outcomes (2030)

Net Cash assumptions vary based on operating cash flow generation in each scenario.

Probability Weighted Price Target (2030): $2.67

Summary: Multiple Compression Risk Analysis shows that despite projected revenue growth in the Base Case, the share price could decline due to valuation multiple compression (from the current ~7x to a more mature 3.5x). The investment only generates positive alpha if the "High Case" SaaS transformation is realized, justifying a continued premium multiple.

6. Qualitative Scorecard

This scorecard evaluates Butterfly Network on ten critical dimensions of corporate quality, utilizing a 1-10 scale.

Overall Blended Score: 6.2 / 10

Summary: Stabilizing, Yet Speculative

7. Conclusion & Investment Thesis

Butterfly Network presents a compelling but complex "post-hype" turnaround opportunity. The company has successfully successfully navigated the most dangerous phase of its lifecycle—the "cash incinerator" phase—and has emerged with a fortress balance sheet and a clear technological differentiator in its semiconductor platform. The "Ultrasound-on-Chip" is not merely a marketing slogan; it is a fundamental cost and form-factor advantage that allows Butterfly to exist at a gross margin profile its crystal-based competitors cannot match at scale.

The investment thesis rests entirely on the success of the "Enterprise Pivot." If Butterfly can successfully deploy Compass AI to large health systems, it solves the two biggest bottlenecks in the POCUS market: billing compliance (revenue for the hospital) and Quality Assurance (liability for the hospital). This transforms the sales conversation from a discretionary clinical device purchase to an infrastructure investment with a quantifiable, hard-dollar ROI.

Key Catalysts to Watch:

1. Compass AI Fleet Deals: Investors must see announcements of large, system-wide deployments in H1 2026 to validate the software thesis.

2. RoHS Regulatory Action: Any signal from the EU regarding the expiration of the lead exemption in 2026/2027 would be a massive, asymmetric tailwind that the market is not currently pricing in.

3. Profitability Crossover: Achieving a break-even or positive adjusted EBITDA quarter (likely late 2026) would be a major psychological milestone that could re-rate the stock.

Risks: The primary risk to the share price is valuation compression. The market currently affords BFLY a growth multiple (~7x Sales) for a company that is currently growing at a value pace (~13%). If the high-growth scenario does not materialize, the stock could drift significantly lower ($2.00–$2.50) simply by re-rating to a standard medical device multiple, even as the business fundamentally improves. Therefore, BFLY is a "Long" for investors who believe in the software transformation, but a "Hold/Avoid" for those looking for deep value safety.

Summary: Execution-Dependent Turnaround

8. Technical Analysis, Price Action & Short-Term Outlook

As of early December 2025, Butterfly Network (BFLY) is trading at $3.06, exhibiting constructive technical behavior. The stock is hovering comfortably above both its 50-day moving average ($2.42) and its 200-day moving average ($2.23), confirming a solid intermediate-term uptrend. The recent "Golden Cross" (where the 50-day MA crosses above the 200-day MA) is a classic bullish signal often followed by momentum buying. The stock recently surged 12% following the Q3 earnings report, indicating that the market is beginning to price in the "turnaround" narrative. Strong support has been established in the $2.80–$3.00 range, bolstered by significant open-market insider buying by Director Larry Robbins. Immediate resistance lies at the analyst target zone of $3.50. If BFLY can break through $3.50 with volume, the next technical leg up could target the $4.00 level; however, failure to hold $2.80 could see a retest of the $2.40 support.

Summary: Bullish Trend Developing